Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+1.30%
+1.73%
-4.23%
+0.36%
LLY
Eli Lilly and Company
$625.65
Chart
$771.75 (-18.93%)
$733.29 (-14.68%)
$837.01 (-25.25%)
$952.74 (-34.33%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.30%
+1.73%
-4.23%
+0.36%
LLY
Eli Lilly and Company
Current Price
$625.65
Login to view Eli Lilly and Company (LLY) recommendation from the last 90 days from financial news and social media.
Chart
$771.75 (-18.93%)
$733.29 (-14.68%)
$837.01 (-25.25%)
$952.74 (-34.33%)
LLY Latest Analysis
Why Eli Lilly Stock Sank 18% This Week. Key PointsEli Lilly is seeing strong growth from its weight loss drugs.
Fri Aug 8, 2025
Eli Lillys Orforglipron Data Is Not Disastrous: Analyst. ) released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron an investigational oral glucagon-.For the primary endpoint orforglipron 36 mg lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using the efficacy estimand below Wall Street’.s .Eli Lilly also released better-than-expected second-quarter earnings on Thursday and.Bank of America (BofA) Securities said on Friday tha
Fri Aug 8, 2025
Expert Outlook: Eli Lilly Through The Eyes Of 4 Analysts. In the last three months 4 analysts have published ratings on Eli Lilly (NYSE:) offering a diverse range of perspectives from ish to bearish.In the table below you'.ll find a summary of their recent ratings revealing the shifting sentiments over the past 30 days and comparing them to the previous months.3100010000110001000000000The 12-month price targets analyzed by analysts offer insights with an average target of $977.0 a high estim
Fri Aug 8, 2025
ETFs in Focus on Eli Lillys Solid Q2 Earnings Weak Obesity Data. LLY tumbles despite solid Q2 results. ETFs like IHE PPH MEDX and MEDI with top exposure may offer buy-the-dip opportunities.
Fri Aug 8, 2025
Eli Lilly Co. Q2 FY2025 Earnings Transcript. ) reported its second-quarter 2025 financial results ahead of the opening bell on Thursday.Below are the transcripts from the Q2 earnings call.This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog please visithttps://www.benzinga.com/apis/for a consultation.Thank you for waiting. Your patience is appreciated. Please hold the line and we’.ll be right back with you. Thank you for holding. We look forward to
Thu Aug 7, 2025
Apple Jumps Eli Lilly Crashes On Worst Day In 25 Years: Whats Moving Markets Thursday?. United States equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President moves in heavyweight names. The ) climbed by 3% on top of the 5.1% gained Wednesday as investors bet the tech giant could sidestep new import duties. The company pledged an additional $100 billion in United States manufacturing investments building on a previously announced $500 billion.The steep
Thu Aug 7, 2025
Eli Lilly raises 2025 revenue guidance to $60B-$62B while expanding GLP-1 pipeline and production.
Thu Aug 7, 2025
Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell This Is A Buy The Dip Moment.
Thu Aug 7, 2025
Earnings call transcript: Eli Lilly Q2 2025 beats forecasts stock drops.
Thu Aug 7, 2025
Eli Lilly Dives 14% On A Shocking Obesity Setback Sending Its Rivals Flying. Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise sending shares of its rival flying.The post Eli Lilly Dives 14% On A Shocking Obesity Setback Sending Its Rivals Flying appeared first on Investor'.s Business Daily.
Thu Aug 7, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings